CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, Inc., a leader in proteomics technology, announced today that Beth Israel Deaconess Medical Center’s (BIDMC) Genomics, Proteomics, Bioinformatics, and Systems Biology Center in Boston, Mass. will be the first site to offer the 7,000-plex SomaScan® Assay kits in their core lab and provide SomaScan data to their clients.
Sign up to receive our news releases
More SomaLogic News
Ixaka Ltd and SomaLogic today announced a research collaboration to support the development of aptamer-based bispecific therapeutics as new anticancer agents that can recruit cytotoxic T cells and induce killing of tumor cells.
SomaLogic, Inc., a global leader in proteomics technology, announced today that it is adding to its list of collaborative agreements with global healthcare innovator, Novo Nordisk. As part of the agreement, Novo Nordisk will expand the use of the SomaScan® technology platform for their drug development research in non-alcoholic steatohepatitis (NASH), cardiovascular disease and diabetes.
SomaLogic, Inc., a global leader in proteomics technology, announced today that their new customizable protein panel products are now available to pharma, biotechnology and academic research customers seeking the power of the company’s proteomics menu of 7,000 proteins.
SomaLogic launches the SomaSignal™ Proteomics for Precision Medicine Initiative with healthcare innovators: Emory University, Intermountain Healthcare, CommonSpirit Health and UCHealth
SomaLogic announced today its SomaSignal™ Proteomics for Precision Medicine Initiative, the first large-scale, clinically focused partnership effort aimed at equipping healthcare providers with the power of proteomic technology to inform decisions at the point of care.
Our presentation at the virtual 2021 Global Nash Congress features Dr. Stephen Williams , who discusses SomaLogics development of serum proteomic tests for liver biopsy components and diagnosis of at-risk NASH. Watch now to learn how these tests can help streamline clinical trials.
As part of the Molecular Medicine Tri-Con virtual conference on February 16, 2021, Dr. Sheri Wilcox of SomaLogic described how the SomaScan Assay has been used to identify protein patterns as surrogates for clinical outcomes, discover proteins associated with disease states, and correlate protein measurements with genetic variants.
Researchers at the University of Cambridge report the largest, systematic assessment of two different affinity-based proteomic platform technologies to date. By truncating the 5000-plex aptamer-based SomaScan® Assay results down to consider approximately 900 overlapping targets on a polyclonal antibody-based assay and running both assays on the same 485 genotyped samples, the researchers successfully replicated most proteogenomic signals on both platforms.
The Colorado BioScience Association (CBSA) recently announced that SomaLogic Chief Executive Officer Roy Smythe was among the seven new members appointed to its board of directors. These new members were selected for their leadership at companies of all stages of commercialization and have expertise in issues that impact Colorado’s life sciences community.